CytokineticsvsEli Lilly and Company

CYTK and LLY stock compared: price, dividend, valuation and results, from SEC filings.

CYTK

Cytokinetics, Incorporated

$51.70

Value $6.4B

-2.77%
CYTK's page

LLY

Eli Lilly and Company

$1,405.09

Value $1.33T

-1.80%
LLY's page

Cytokinetics (CYTK) has a market value of $6.4B and Eli Lilly and Company (LLY) $1.33T. Over the last year, with dividends, CYTK moved -22.2% and LLY +38.0%. Dividend yield: CYTK none, LLY 0.45%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CYTK$6.4B

    LLY$1.33T

    LLY is 208 times CYTK

  • Revenue, 12 months

    CYTK$113M

    LLY$86.5B

    LLY is 763 times CYTK

  • Net income, 12 months

    CYTK-$778M

    LLY$27.6B

  • Operating margin

    CYTK-625.2%

    LLY–

  • ROIC

    CYTK–

    LLY35.5%

  • P/E

    CYTK–

    LLY48.1

  • Dividend yield

    CYTK0.0%

    LLY0.4%

    0.5 points apart

  • 5-year return

    CYTK+31.7%

    LLY+469.6%

    437.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CYTK+31.7%

LLY+469.6%

20040060020222023202420252026
Returns by period
PeriodCYTKWith dividendsLLYWith dividends
1 year since November 14, 2025-22.2%Price -22.2%+38.0%Price +37.1%
3 years since November 17, 2023+59.3%+16.8% a yearPrice +59.3%+142.4%+34.3% a yearPrice +137.6%
5 years since November 16, 2021+31.7%+5.7% a yearPrice +31.7%+469.6%+41.6% a yearPrice +445.6%
10 years since November 17, 2016+365.7%+16.6% a yearPrice +365.7%+2,004.7%+35.6% a yearPrice +1,709.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CYTKCytokineticsLLYEli Lilly and Company

Valuation

CYTKLLY
Valuation
Price$51.70$1,405.09
Market value$6.4B$1.33T
Enterprise value (EV)–$1.37T
P/E–48.1
P/E, 5-year median–49.9
P/B–32.9
EV/EBIT–39.4
Free cash flow yield–1.5%

Results and growth

CYTKLLY
Results and growth
Revenue, 12 months$113M$86.5B
Net income, 12 months-$778M$27.6B
Free cash flow, 12 months-$589M$19.7B
Earnings per share, 12 months-$6.04$30.81
Revenue growth, year on year376.6%44.7%
Revenue growth a year, past+9.5%over 5 years+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

CYTKLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin-625.2%–
Net margin-686.6%31.9%
ROIC–35.5%
ROE–88.6%

Balance sheet

CYTKLLY
Balance sheet
Cash$1.6B$4.9B
Total debt–$49.5B
Net debt / EBITDA–1.2
Interest cover-15.5×38.9×

Dividends and buybacks

CYTKLLY
Dividends and buybacks
Dividend yield–0.4%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CYTK or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Cytokinetics or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.33T) is about 208.2 times Cytokinetics ($6.4B), at today's prices.

How did CYTK and LLY stock do over the last 10 years?

Since November 17, 2016, CYTK's price moved +365.7% and LLY's +1,709.4%. With dividends: CYTK +365.7% (+16.6% a year), LLY +2,004.7% (+35.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, CYTK or LLY?

The dividend yield at today's price is none for Cytokinetics and 0.45% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Cytokinetics or Eli Lilly and Company?

Over the last twelve months, the net margin was -686.6% for Cytokinetics and 31.9% for Eli Lilly and Company, and the operating margin -625.2% and –. Revenue was $113M and $86.5B.

Which is the better investment, Cytokinetics or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.